Information about Ziprasidone
Ziprasidone is an atypical antipsychotic used in the treatment of schizophrenia and bipolar disorder.
Liver safety of Ziprasidone
Use of ziprasidone has not been consistently associated with serum enzyme elevations and has yet to be linked to instances of clinically apparent acute liver injury.
Mechanism of action of Ziprasidone
Ziprasidone (zi pras' i done) is a benzisothiazolyl piperazine-type atypical antipsychotic that appears to act as a dopamine type 2 (D2) and serotonin (5-HT2) receptor antagonist. It also has moderate activity against α-adrenergic and histamine receptors. Ziprasidone is indicated for the therapy of schizophrenia and as either monotherapy or adjunctive therapy for acute manic episodes and maintenance therapy for manic and mixed episodes in bipolar disorder.
FDA approval information for Ziprasidone
Ziprasidone was approved for use in the United States in 2001 and is widely used.
Dosage and administration for Ziprasidone
Ziprasidone is available as capsules of 20, 40, 60 and 80 mg generically and under the brand name Geodon. It is also available as an oral suspension and as a solution for intramuscular injection. The typical initial dose is 20 mg twice daily, which can be increased to a maximum of 100 mg twice daily.
Side effects of Ziprasidone
Common side effects include somnolence, dizziness, restlessness, fatigue, headache, nausea, dyspepsia, anorexia, dry mouth and blurred vision. weight gain is uncommon and extrapyramidal symptoms occur in about 5% of patients.
Second Generation (Atypicals)
- Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Olanzapine, Paliperidone, Pimavanserin, Quetiapine, Risperidone, Ziprasidone